Full Text View
Tabular View
No Study Results Posted
Related Studies
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
This study has been suspended.
Study NCT00596830   Information provided by Pfizer
First Received: January 3, 2008   Last Updated: November 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Squamous Cell
Carcinoma, Adenosquamous
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Additional conditions recognized in this trial
Carcinoma
More general conditions related to this trial
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Carboplatin + Paclitaxel
Additional drug interventions recognized in this trial
Carboplatin
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services